{"meshTagsMajor":["Neoadjuvant Therapy"],"meshTags":["Antineoplastic Agents, Hormonal","Clinical Trials as Topic","Disease-Free Survival","Humans","Male","Neoadjuvant Therapy","Neoplasm Staging","Prostatectomy","Prostatic Neoplasms"],"meshMinor":["Antineoplastic Agents, Hormonal","Clinical Trials as Topic","Disease-Free Survival","Humans","Male","Neoplasm Staging","Prostatectomy","Prostatic Neoplasms"],"genes":["cT1-2","margin and PSA failure"],"publicationTypes":["English Abstract","Journal Article","Review"],"abstract":"The efficacy of neoadjuvant hormone therapy and radical prostatectomy for cT1-2 prostate cancer have been reported to be negative from some randomized prospective studies. On the other hand, radical prostatectomy alone for cT3 prostate cancer is understood as out of indication because of high rate of positive surgical margin and PSA failure. Several investigators have examined the role of neoadjuvant hormone therapy before radical prostatectomy for cT3 prostate cancer to improve outcome. This document was reviewed the literature whether neoadjuvant hormone therapy is beneficial or not, for organ confined prostate cancer and for locally advanced prostate cancer, and presented our extended resection of prostate with neoadjuvant hormone therapy is improved the results in cT3 prostate cancer.","title":"[Radical prostatectomy with neoadjuvant hormone therapy for cT3 prostate cancer].","pubmedId":"15714978"}